110 related articles for article (PubMed ID: 35942328)
1. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer.
Connelly GG; Kirkland OO; Bohannon S; Lim DC; Wilson RM; Richards EJ; Tay DM; Jee H; Hellinger RD; Hoang NK; Hao L; Chhabra A; Martin-Alonso C; Tan EKW; Koehler AN; Yaffe MB; London WB; Lee PY; Krammer F; Bohannon RC; Bhatia SN; Sikes HD; Li H
Cell Rep Methods; 2022 Aug; 2(8):100273. PubMed ID: 35942328
[TBL] [Abstract][Full Text] [Related]
2. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
6. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
7. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
8. Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity-lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices.
McGrath J; O'Doherty L; Conlon N; Dunne J; Brady G; Ibrahim A; McCormack W; Walsh C; Domegan L; Walsh S; Kenny C; Allen N; Fleming C; Bergin C
Front Public Health; 2023; 11():1245464. PubMed ID: 37841735
[TBL] [Abstract][Full Text] [Related]
9. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
10. Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera.
Streif S; Neckermann P; Spitzenberg C; Weiss K; Hoecherl K; Kulikowski K; Hahner S; Noelting C; Einhauser S; Peterhoff D; Asam C; Wagner R; Baeumner AJ
Anal Bioanal Chem; 2023 Mar; 415(8):1421-1435. PubMed ID: 36754874
[TBL] [Abstract][Full Text] [Related]
11. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
12. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.
Resman Rus K; Korva M; Knap N; Avšič Županc T; Poljak M
J Clin Virol; 2021 Jun; 139():104820. PubMed ID: 33865031
[TBL] [Abstract][Full Text] [Related]
13. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
Pieri M; Nicolai E; Nuccetelli M; Sarubbi S; Tomassetti F; Pelagalli M; Minieri M; Terrinoni A; Bernardini S
Arch Virol; 2022 May; 167(5):1285-1291. PubMed ID: 35377034
[TBL] [Abstract][Full Text] [Related]
14. Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody.
Duan X; Shi Y; Zhang X; Ge X; Fan R; Guo J; Li Y; Li G; Ding Y; Osman RA; Jiang W; Sun J; Luan X; Zhang G
Biosens Bioelectron; 2022 Mar; 199():113883. PubMed ID: 34942543
[TBL] [Abstract][Full Text] [Related]
15. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
Fulford TS; Van H; Gherardin NA; Zheng S; Ciula M; Drummer HE; Redmond S; Tan HX; Boo I; Center RJ; Li F; Grimley SL; Wines BD; Nguyen THO; Mordant FL; Ellenberg P; Rowntree LC; Kedzierski L; Cheng AC; Doolan DL; Matthews G; Bond K; Hogarth PM; McQuilten Z; Subbarao K; Kedzierska K; Juno JA; Wheatley AK; Kent SJ; Williamson DA; Purcell DFJ; Anderson DA; Godfrey DI
EBioMedicine; 2021 Dec; 74():103729. PubMed ID: 34871960
[TBL] [Abstract][Full Text] [Related]
16. Rapid determination of SARS-CoV-2 antibody neutralization titer using Bio-Rad Bio-Plex correlates strongly with pseudovirus-determined neutralization titer.
Heaps AL; Sobolewski MD; Jacobs JL; Gordon KC; Haidar G; Mellors JW; Parikh UM
J Virol Methods; 2023 Jun; 316():114726. PubMed ID: 36996908
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response.
Liu Z; Yang C; Zhang H; Cao G; Wang S; Yin S; Wang Y
Front Immunol; 2022; 13():960094. PubMed ID: 36389744
[TBL] [Abstract][Full Text] [Related]
18. Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.
Lake DF; Roeder AJ; Kaleta E; Jasbi P; Pfeffer K; Koelbela C; Periasamy S; Kuzmina N; Bukreyev A; Grys TE; Wu L; Mills JR; McAulay K; Gonzalez-Moa M; Seit-Nebi A; Svarovsky S
J Clin Virol; 2021 Dec; 145():105024. PubMed ID: 34781240
[TBL] [Abstract][Full Text] [Related]
19. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
20. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
